낭포성 섬유증 치료제 : 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Cystic Fibrosis Therapeutics Market was valued at USD 18.1 billion in 2025 and is estimated to grow at a CAGR of 16% to reach USD 79.7 billion by 2035.

Market expansion is driven by the increasing incidence of cystic fibrosis and the growing focus on improving treatment effectiveness and patient outcomes. Rising awareness regarding early diagnosis and advancements in diagnostic technologies are supporting the timely identification of the condition, which is encouraging the adoption of targeted therapies. Continued investment in research and development is accelerating innovation in treatment approaches, leading to the introduction of more advanced and effective therapeutic solutions. Cystic fibrosis therapeutics include a wide range of treatment options designed to manage symptoms and improve the quality of life for affected individuals. As a genetic condition impacting multiple organ systems, the need for comprehensive and specialized treatment strategies is increasing. The market is benefiting from the emergence of advanced therapies and improvements in existing treatment modalities, which are enhancing clinical outcomes. Ongoing innovation and the expanding availability of treatment options are creating new growth opportunities and strengthening the overall outlook of the cystic fibrosis therapeutics market.

The medication segment accounted for USD 16.2 billion in 2025, maintaining a dominant share within the market. This segment includes multiple categories of drug therapies designed to manage symptoms and address underlying disease mechanisms. Increasing advancements in pharmaceutical development are driving demand for effective medications that improve patient response and overall treatment outcomes. The availability of targeted therapies that focus on specific disease characteristics is contributing to the segment's strong performance. Continuous progress in drug development is enhancing treatment efficacy, supporting long-term disease management, and reinforcing the importance of medication-based approaches in the cystic fibrosis therapeutics market.

The segment below 18 years held a share of 76.9% in 2025, reflecting the significant impact of the condition within younger populations. Early onset of the disease necessitates prompt diagnosis and timely intervention, which is driving demand for specialized pediatric treatment options. Increased focus on early-stage disease management and the availability of advanced diagnostic tools are supporting higher treatment adoption in this age group. Caregiver awareness and improved access to healthcare services are further contributing to segment growth. In addition, ongoing research efforts and regulatory support for pediatric treatments are strengthening the segment's position and ensuring continued dominance throughout the forecast period.

North America Cystic Fibrosis Therapeutics Market accounted for 74.5% share in 2025, driven by strong healthcare infrastructure and high accessibility to advanced treatment options. The region benefits from the presence of leading pharmaceutical companies and well-established healthcare systems that support widespread adoption of innovative therapies. Favorable reimbursement frameworks and insurance coverage are enabling broader patient access to high-cost treatments. Continued focus on research, early diagnosis programs, and treatment innovation is supporting sustained market growth. The region's commitment to improving patient outcomes and expanding access to care is reinforcing its leadership in the global cystic fibrosis therapeutics market.

Key players operating in the Global Cystic Fibrosis Therapeutics Market include Alcresta Therapeutics, Baxter, Chiesi Farmaceutici, F. Hoffmann-La Roche, Gilead, Koninklijke Philips, Lupin, Monaghan Medical, Novartis, Savara, Sionna Therapeutics, Teva Pharmaceutical Industries, and Vertex Pharmaceuticals. Companies in the Global Cystic Fibrosis Therapeutics Market are adopting a range of strategic initiatives to strengthen their market position and expand their global presence. Industry participants are heavily investing in research and development to advance innovative therapies and improve treatment effectiveness. Strategic collaborations, partnerships, and licensing agreements are being pursued to accelerate drug development and enhance technological capabilities. Organizations are also focusing on expanding their product portfolios to address diverse patient needs and improve treatment accessibility. Efforts to secure regulatory approvals and streamline commercialization processes are further supporting market expansion.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Age group trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence rate of cystic fibrosis patient population
    • 3.2.1.2 Advancements in CFTR modulator therapy
    • 3.2.1.3 Growing investment in research and development
    • 3.2.1.4 Government support and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Adverse side effects of current therapies
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of combination therapies and next-generation CFTR modulators
    • 3.2.3.2 Integration of digital health and remote patient monitoring
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pipeline analysis (Driven by Primary Research)
• 3.7 Epidemiology scenario (Driven by Primary Research)
• 3.8 Impact of AI and Generative AI on the market
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
  • 5.1.1 Medication
    • 5.1.1.1 By drug class
      • 5.1.1.1.1 CFTR modulators
      • 5.1.1.1.2 Mucolytic agents
      • 5.1.1.1.3 Bronchodilators
      • 5.1.1.1.4 Anti-infective agents
      • 5.1.1.1.5 Pancreatic enzyme supplements
      • 5.1.1.1.6 Other drug classes
  • 5.1.2 By route of administration
    • 5.1.2.1 Oral
    • 5.1.2.2 Inhalation
  • 5.1.3 By distribution channel
    • 5.1.3.1 Hospital pharmacies
    • 5.1.3.2 Retail pharmacies
    • 5.1.3.3 Online pharmacies
• 5.2 Non-medication

Chapter 6 Market Estimates and Forecast, By Age Group, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Below 18 years
• 6.3 18 - 40 years
• 6.4 41 and above

Chapter 7 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Netherlands
  • 7.3.7 Ireland
  • 7.3.8 Denmark
• 7.4 Asia Pacific
  • 7.4.1 India
  • 7.4.2 Japan
  • 7.4.3 Australia
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Alcresta Therapeutics
• 8.2 Baxter
• 8.3 Chiesi Farmaceutici
• 8.4 F. Hoffmann-La Roche
• 8.5 Gilead
• 8.6 Koninklijke Philips
• 8.7 Lupin
• 8.8 Monaghan Medical
• 8.9 Novartis
• 8.10 Savara
• 8.11 Sionna Therapeutics
• 8.12 Teva Pharmaceutical Industries
• 8.13 Vertex Pharmaceuticals